Table 3.
Barrett's screening patients: increased detection of Barrett's esophagus or dysplasia
| Forceps biopsy results | |||||
|---|---|---|---|---|---|
| WATS results | HGD/EAC | IND/LGD | NDBE | No BE | Total |
| HGD/EAC | 7 | 0 | 2 | 3 | 12 |
| IND/LGD | 2 | 3 | 41 | 61 | 107 |
| NDBE | 0 | 19 | 479 | 2,046 | 2,544 |
| Negative | 1 | 7 | 440 | 7,301 | 7,749 |
| Total | 10 | 29 | 962 | 9,411 | 10,412 |
| Increased detection with WATS | |||||
| Relative increase vs. forceps | Absolute increase vs. forceps | Number needed to test | |||
| All Barrett's esophagus | 213% (95% CI: 197%–230%) | 19.7% | 5.1 | ||
| Dysplastic Barrett's | 274% (95% CI: 194%–414%) | 1.0% | 97.3 | ||
BE, Barrett's esophagus; EAC, esophageal adenocarcinoma; HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.